No abstract available
Keywords:
Alirocumab; ODYSSEY outcome study; PCSK inhibitors; major adverse cardiac events; mortality.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Anticholesteremic Agents*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
alirocumab